Insights from 2023 ASH Annual Meeting
Avatar

ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatinib in Pts With Previously Treated Ph+ CML in Chronic or Accelerated Phase"

By Insights from 2023 ASH Annual Meeting FEATURING Jorge Cortés
By Insights from 2023 ASH Annual Meeting FEATURING Jorge Cortés
0 views
January 16, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Recommended

AUTOPLAY
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
04:16
Luke Fletcher

Efficacy and Safety of Asciminib in Ph+ CML

09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
07:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …

Feat. E. Atallah
23:15
Rush University Medical Center

Is Post-HSCT Maintenance the SOC for AML?

Feat. M. Levis
16:25
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

Feat. N. Cross
19:15
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML - Are We Doing It Right?

Feat. J. Cortés
17:30
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Rational TKI Choice in CML

Feat. M. Deininger
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
17:47
The University of Alabama at Birmingham School of Medicine

Treating CML Patients With TKI Resistance vs. TKI Intolerance

Feat. O. Jamy
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
27:47
City of Hope

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

Feat. I. Amanam
20:43
Indy Hematology Review

Controversies in the Management of CML in 2024

Feat. R. Larson
16:52
Winship Cancer Institute - Emory University

Updates on Myeloproliferative Neoplasms Including CML

Feat. A. Hunter
12:09
Pooja Khandelwal

Treating Fibrosis and Inflammation in GvHD

06:26
Akriti Jain

Managing TKI AEs in CML: Thrombocytopenia, Hypertension, Pancreatic …

03:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatin…

Feat. E. Jabbour
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
18:55
International CML Foundation

iCMLf Conversations: CML Clinical Highlights of EHA 2023

Feat. A. Hochhaus
23:06
Indy Hematology Review

Understanding and Addressing the Challenges in CML in 2024

Feat. R. Larson